Dan Shores
Partner Rothwell Figg
Dan Shores is a partner at Rothwell Figg and founder of its Boston office. He has over 20 years of patent law experience and serves companies operating in a wide range of spaces including biotech, tech, AI, medical device, materials and energy. Examples of these technologies include mRNA; lipid nanoparticles; antibody drug conjugates (ADCs); CAR-T therapies; CRISPR; oligonucleotides; genetically engineered swine organs for xenotransplantation; AI for drug discovery; probes for tissue investigation; small molecule pharma; and numerous other technologies. Dan and his team help build patent portfolios, negotiate licenses and strategic collaborations, develop and implement effective IP strategies, litigate complex patent disputes, and conduct due diligence and landscape investigations. Dan is a registered patent attorney licensed to practice before the United States Patent and Trademark Office, and is admitted to practice law in Massachusetts and in the District of Columbia. He is a member of the bars of the Supreme Court of the United States, United States Court of Appeals for the Federal Circuit, and United States District Court for the District of Massachusetts.
Seminars
In today’s increasingly crowded ADC landscape, savvy IP strategy is critical for commercial success. This workshop explores how innovators can identify the IP opportunities and risks when developing a novel conjugate asset. Gain practical insights into competitive IP positioning, covering the type and timing of your own IP creation, as well as how to manage freedom-to-operate challenges. The workshop will demonstrate how to use IP strategy to enable your ADC or conjugate asset to reach its full commercial potential.
Key Questions:
- Reviewing approaches for leveraging known technology to minimise patent infringement risk
- Understanding the risks and opportunities of using known technology as the starting point for innovation
- Exploring strategies for protecting novel ADC assets and position them to withstand competitive challenges
